Clinical trials: Invasive Pneumococcal Disease
- Condition Invasive Pneumococcal Disease
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Pneumococcal Infections
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)
This study will evaluate whether the aluminum-adjuvanted or the non-adjuvanted formulation of the candidate pneumococcal vaccine (V114) is non-inferior to Prevnar 13® based on immune responses to the 13 serotypes in common…
- Trial name
- NCT01215188
- Testing
- V114 Aluminum-adjuvanted, V114 Non-adjuvanted, Prevnar 13®
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Neisseria Meningitidis (Bacterial Meningitis), Invasive Pneumococcal Disease (IPD)
Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)
The purpose of this study in healthy toddlers who have not previously been immunized against MenC infection and who completed their primary immunization series with PCV-7 (3 vaccinations) during infancy is to demonstrate that the…
- Trial name
- NCT00617760
- Testing
- Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7), 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7), Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)
- Where
- 27 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Diseases
Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey
The aim of this study is to specify the serotype distribution of Streptococcus pneumoniae that causes invasive diseases at children and adults in Turkey.
- Trial name
- NCT01810861
- Testing
- There is no intervention in this study
- Where
- 32 sites in Turkey (Türkiye)
- Volunteers
- 922 people
- Sponsor
- Pfizer
Infections, Streptococcal, Streptococcus Pneumoniae
Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
The aim of this study is to assess the effectiveness of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), administered according to different vaccination schedules, against invasive disease caused by S.
- Trial name
- FinIP (NCT00861380)
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine), GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)
- Where
- Finland
- Volunteers
- 41,188 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
Child Pneumococcal Serotype Epidemiology In Greece
Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia, and pneumococcal meningitis among infants and children worldwide.
- Trial name
- NCT01111214
- Testing
- no intervention
- Where
- 9 sites in Greece
- Volunteers
- 457 people
- Sponsor
- Pfizer
Invasive Pneumococcal Disease
Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine
The primary purpose of this study is to evaluate the immune response to 13-valent pneumococcal conjugate vaccine (13vPnCV) in children who as infants received either a complete series of PnCV versus a combination of PnCV and…
- Trial name
- REPLAY (NCT00853749)
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), Blood draw
- Where
- 2 sites in Iceland
- Volunteers
- 89 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumonia, Meningitis
Colombia Epidemiologic Surveillance Study
The study will determine the reduction in invasive pneumococcal disease (IPD) after the introduction of a National Immunization Program with PCV-7 in Bogota.
- Conditions
- Pneumonia, Meningitis, Bacteremia, Sepsis
- Trial name
- LEAP II (NCT00428051)
- Testing
- Surveillance
- Where
- 3 sites in Brazil, Colombia and 1 more
- Volunteers
- 32,867 people
- Sponsor
- Pfizer
Invasive Pneumococcal Disease
Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.
- Trial name
- NCT01128439
- Testing
- No intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Infections, Streptococcal, Streptococcus Pneumoniae
Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A
The aim of this study is to assess the effectiveness of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A) in preventing invasive disease caused by S. pneumoniae or H.
- Trial name
- NCT00839254
- Testing
- Pneumococcal conjugate vaccine Synflorix (GSK1024850A), GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine), GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)
- Where
- 15 sites in Finland
- Volunteers
- 6,181 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants
The primary aim of the study is to demonstrate that an investigational 4-dose presentation of the 10Pn-PD-DiT vaccine with preservative is non-inferior to the licensed presentation of Synflorix (preservative-free) in terms of…
- Trial name
- NCT02447432
- Testing
- Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation), Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation), DTPw-HBV/Hib
- Where
- Bangladesh
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India
This study is to describe the safety and immunogenicity of 13vPnC in Indian adults 50 to 65 years of age and in Indian children 6 to 17 years of age.
- Trial name
- NCT02034877
- Testing
- 13-valent Pneumococcal conjugate vaccine, Blood sample collection
- Where
- 16 sites in India
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease, Invasive
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
The goal of this clinical trial is to evaluate the immunogenicity and safety of a novel 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13-TT) as compared to Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13)…
- Trial name
- NCT05934890
- Testing
- Walvax PCV13-TT, Pfizer PCV13
- Where
- 2 sites in Indonesia
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Pneumococcal Disease, Invasive
Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants
Phase 2 trial to evaluate safety and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in Healthy Infants
- Trial name
- NCT06790290
- Testing
- Formulation B, Formulation C, Formulation D
- Where
- 3 sites in Philippines
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- Inventprise Inc.
Invasive Pneumococcal Disease
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)
- Trial name
- NCT00227188
- Testing
- Pneumococcal 7-valent conjugate vaccine Prevnar
- Where
- Spain
- Volunteers
- 408 people
- Sponsor
- Pfizer